New Study Examines Cost-Effectiveness, Equity, Caregiver Burden, and Other Value Elements in 20 ICER Reports

A new article, published in the Journal of Managed Care and Specialty Pharmacy, examines 32 value elements, including health equity and caregiver burden, usually not considered by HTAs (health technology assessments) such as ICER (Institute of Clinical and Economic Review). The authors note that more value elements were identified in sickle cell disease and in inherited retinal disease, while only seven value elements were identified in the context of cardiovascular disease. The authors note that considering a wider range of factors to determine value will draw research efforts to areas in greater need of therapeutic options.

The authors conclude, “The presence of broader value elements varied across diseases, with less cost-effective treatments more likely to have a higher number of relevant broader value elements. Inclusion of all relevant value elements in value assessments will more appropriately incentivize innovation and improve allocation of research funding.” Read more here.

(Source: Shafrin et al., JMPC, May 2021)